Answers are grounded in this paper and cite their sources.
In vitro study demonstrates enhanced target affinity and cytotoxicity of a cyclic Grb2–SH2 peptide mimic in A431 cells, highlighting its therapeutic potential.
A small peptide mimic of the Grb2-SH2 domain, which was previously prepared through the template-assisted click approach and exhibited selective A431 tumor growth inhibition both in vitro and in vivo, was further elaborated on to enhance the interaction with target phosphorylated proteins. A conformationally fixed analog was efficiently synthesized by solid-supported ring-closing metathesis and Cu(i)/His-mediated self-activating Huisgen [3+2] cycloadditon as the key steps, and exhibited a 10-fold enhanced affinity to a phosphorylated peptide, a truncated peptide analog of the Grb2-SH2-interacting phosphoproteins. A stronger interaction with the target phosphorylated proteins gave this cyclic analog cytotoxic activity in A431 cells.
No takes yet. Share an insight, caveat, or question.
Iwata et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: